Author

M. J. Hesse

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 2 Approach:comparative / phylogenetic analysis· 1

Frequent Co-Authors

D. Dovala· 3 shared D. K. Nomura· 3 shared J. M. McKenna· 3 shared M. Schirle· 3 shared J. A. Tallarico· 2 shared C. C. Ward· 1 shared C. M. Zammit· 1 shared D. Fuller· 1 shared

Activity by Year

2022-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersBiochemistry

D. Dovala

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

BiochemistrybioRxivPreprintDec 19, 2022

Targeted Protein Degradation through E2 Recruitment

N. Forte, D. Dovala, M. J. Hesse…·D. K. Nomura

This study identifies a covalent recruiter for the E2 ubiquitin conjugating enzyme UBE2D, enabling targeted protein degradation via PROTACs.

DOI 10.1101/2022.12.19.520812

comparative / phylogenetic analysisdrug response / drug discovery

𝕏 PostBluesky

BiochemistrybioRxivNov 4, 2022

Rational Chemical Design of Molecular Glue Degraders

E. S. Toriki, J. W. Papatzimas, K. Nishikawa…·D. K. Nomura

This paper develops a strategy to convert protein-targeting ligands into molecular glue degraders by identifying a covalent handle that induces proteasome-mediated degradation of target proteins.

DOI 10.1021/acscentsci.2c01317

experimental assaydrug response / drug discovery

𝕏 PostBluesky

BiochemistrybioRxivMar 5, 2022

Discovery of Potent Pyrazoline-Based Covalent SARS-CoV-2 Main Protease Inhibitors

P. Moon, L. Boike, D. Dovala…·D. K. Nomura

This study identifies and optimizes potent pyrazoline-based covalent inhibitors of SARS-CoV-2 Mpro, showing activity against multiple coronaviruses.

DOI 10.1002/cbic.202300116

experimental assaydrug response / drug discovery

𝕏 PostBluesky